Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Federal research grant for novel genetic approach to arthritis

Oct. 11, 1996

Celecoxib development status in Japan

Oct. 11, 1996

Searle continues to investigate COX-2 inhibitors for inflammation

Oct. 11, 1996

Pfizer halts U.S. development of tenidap for rheumatoid arthritis

Oct. 4, 1996

Enzyme inhibitor for autoimmune diseases isolated by Japanese researchers

Oct. 4, 1996

Mercian investigators report new antiarthritic compounds

Oct. 4, 1996

Merck Frosst discloses a new series of COX-2 inhibitors

Oct. 4, 1996

Matrix metalloproteinase inhibitors disclosed by Roche Bioscience

Oct. 4, 1996

More COX-2 inhibitors from Searle

Oct. 4, 1996

TAK-603 in clinical development for arthritis

Sep. 27, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.